B O O K - American College of Rheumatology

More documents

Recommendations

Info

abstract KEYWORD INDEX type I IFN signature 1084 type I interferon 1188, 1379 type II collagen 1709, 2235 typing 2142 tyrosine kinase 293, 1536 tyrosine kinase inhibitor 286 tyrosine phosphorylation 609 UA 1371 U ulcers 593, 1045, 1217, 1222, 1239, 1278, 1657 ultrasonography 889 ultrasound 45, 127, 455, 889, 1038, 1055, 1169, 1220, 1237, 1263, 1302, 1397, 1614, 1616, 1617, 1618, 1620, 1621, 1624, 1626, 1629, 1630, 1631, 1633, 1634, 1635, 1636, 1754, 1962, 2220, 2221, 2222, 2223, 2225 undercarboxylated osteocalcin 983, 1773 undifferentiated arthritis 658, 659, 1396, 1785 undifferentiated spondyloarthritis 2272 unexplained symptoms 170 unfolded protein response 634, 1376, 1965 urantide 618 URAT1 164 urate lowering therapy 2088 uric acid 144, 150, 154, 157, 160, 161, 164, 165, 877, 884, 992, 1367, 1556, 1574, 1616, 2153 uricase 144 US adults 687 USpA 1925 utility 787 utilization review 60, 969, 1675, 1864 uveitis 230, 234, 546, 904, 1308, 1447, 1670, 1933 V vaccination 849 vaccines 9, 224, 235, 236, 323, 450, 457, 466, 478, 481, 645, 697, 792, 1037, 1238, 1437, 1440, 1694, 1917, 2043 validation 625, 659, 1774 validity 1749, 2061, 2068 value of information 759 Van der Heijde modified Sharp score 1392 variant 2177 varicella zoster virus 421 varicocele 513 varus thrust 195, 202, 2101 vascular involvement 1285 vascular remodelling 1314 vascular stiffness 519, 1200 vasculitis 126, 680, 774, 822, 1045, 1207, 1249, 1275, 1280, 1284, 1285, 1286, 1287, 1290, 1291, 1297, 1298, 1299, 1301, 1302, 1303, 1305, 1307, 1308, 1313, 1314, 1315, 1326, 1512, 1646, 1663, 1669, 1673, 1675, 1691, 1695, 1705, 2009, 2010, 2011, 2012, 2013, 2014, 2016, 2017, 2018, 2019, 2020, 2021, 2023, 2024, 2025, 2026, 2027, 2029, 2030, 2032, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2048, 2107, 2131, 2198, 2200, 2201, 2203 VCAM-1 492 VEGF 1418 venous thromboembolism 53, 78, 1539 vertebral fracture assessment by morphometry (VFA) 976 very early presentation 661 vestibuloauditory symptoms 1675 veterans 1099, 1792 vibratory sense 205 viral conversion 510 virtual teaching 44 viruses 804, 1197, 1478, 1642, 1694, 1891 visfatin 619, 1514 visit frequency 1868, 1869 visual ischemic manifestations 1301 vitamin D 310, 706, 1163, 1180, 2030 vitamin K 1773 vitamins 252, 310, 872, 1574 VLA-4 865 voxel based morphometry (VBM) 1167 VpreB 1589 vulnerable coronary plaque 1046, 1443, 2164, 2165 W walking 2141 walking speed 2133 watchful waiting 992 web-based 44 Wegener’s granulomatosis 676, 677, 678, 679, 681, 2009, 2012, 2014, 2018, 2021, 2022, 2026, 2028, 2029, 2031, 2034, 2043, 2047, 2049 widespread pain 550 withholding of therapy 1381 Wnt 601, 629, 1468, 1503 Wnt pathway 624 Wnt signaling 716 WOMAC 706 women 1546, 2132 women’s health 165, 325, 347, 447, 974, 1063, 2083, 2092 work activity limitation 2141 work disability 1211, 1349, 2139 work limitations 2069, 2138 work productivity 51, 2195 working age 2069, 2138 worst case 2281 wound fluid analysis 1239 X chromosome 2004 xenotropic murine leukemia virus-related virus 804 x-ray findings 185 X Y young arthritis patients 1345 Zc3h12a 364 zero-inflation 1564 zoledronic acid 2156 zymosan-induced arthritis 1713 Z 374 2010 Program Book
Abelson, Abby Goulder, MD Education Disclosure:Nothing to Disclose Abraham, David, MD Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Pathogenesis, Animal Models and Genetics Disclosure:Nothing to Disclose Adams, Barbara S, MD Pediatric Rheumatology - Pathogenesis and Genetics: Biological Basis for Pediatric Rheumatic Disease Disclosure: Aringer, Martin Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety and Efficacy I Disclosure: Centocor, 2; Roche, 5 Asahara, Hiroshi, MD, PhD Biology and Pathology of Bone and Joint: Molecular Basis of Osteoarthritis Disclosure:Nothing to Disclose Backman, Catherine L, PhD, OT(C) Keep Working with Arthritis Disclosure: Nothing to Disclose A B Baer, Alan N, MD Sjögren’s Syndrome Disclosure:Nothing to Disclose Baron, Murray Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Aspects and Therapeutics II Disclosure: Nothing to Disclose Birnbaum, Neal S, MD Rheumatoid Arthritis - Clinical Aspects: Preclinical RA and Early RA I Disclosure: AMgen/Pfizer, Amgen, Centocor, UCB, Genentech, 8 Block, Joel A, MD Osteoarthritis - Clinical Aspects: Pain and Biomechanics Disclosure: KAI / NIH, 9; NiCOx, 5; OA and Cartilage, 9; Pleiad, 5 Brandenstein, Jane S, MD Physical and Psychosocial Challenges in Scleroderma Braun, Juergen, MD Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Imaging I Breban, Maxime A Spondylarthritis and Psoriatic Arthritis: Pathogenesis, Etiology, and Animal Models Disclosure: Nothing to Disclose Brunner, Hermine, MD ACR/ARHP Combined Pediatric Rheumatology: Clinical and Therapeutic Aspects: Quality of Life in Children and Adolescents with Arthritis Buch, Maya H, MD, PhD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety and Efficacy I Disclosure: Abbott, 5; Pfizer/Wyeth, 5; Roche, 5 Bunyard, Matthew P, MD Quality Measures and Innovation in Practice Management and Care Delivery Disclosure: Nothing to Disclose C Carette, Simon, MD ANCA-associated Vasculitis I Disclosure:Nothing to Disclose Carlone, Joyce P, MD Rheumatoid Arthritis: From Clinic to Home Disclosure:Nothing to Disclose Chakravarty, Eliza F, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Renal Disclosure:Nothing to Disclose Chatham, W. Wimm, MD Miscellaneous Rheumatic and Inflammatory Diseases Disclosure: Nothing to Disclose Chen, Pojen P, MD Antiphospholipid Syndrome I Disclosure:Nothing to Disclose Choy, Ernest, MD Rheumatoid Arthritis - Clinical Aspects: Radiographic and Other Outcomes in RA IV Disclosure: Abbott Immunology Laboratories, 5; Astra Zeneca, 5; Chelsea Therapeutics, 2; Chugai Pharma, 5; Chugai Pharma, 8; Eli Lilly, 5; Eli Lilly, 8; GSK, 5; Jazz Pharmaceuticals, 2; Jazz Pharmaceuticals, 5; MSD, 2; Pfizer, 5; Roche, 2; Roche, 5; Roche, 8; Synovate, 5; UCB, 2l UCB, 5; UCB, 8; Wyeth, 5 Cibere, Jolanda Epidemiology and Health Services Research: General Interest Disclosure: Amgen Inc, 2l Centocor Research and Development Inc, 2 Clancy, Robert M, MD Innate Immunity and Rheumatic Disease Disclosure:Nothing to Disclose Clauw, Daniel J, MD Fibromyalgia and Soft Tissue Disorders Disclosure:Nothing to Disclose Clegg, Daniel O, MD Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Biomarkers II Disclosure:Nothing to Disclose Cohen, Philip L, MD Systemic Lupus Erythematosus - Animal Models Disclosure: Nothing to Disclose Cooper, Robert G, MD Muscle Biology, Myositis and Myopathies: Insights into the Pathogenesis and Outcomes of Myositis Disclosure:Nothing to Disclose Cohen, Philip L, MD Systemic Lupus Erythematosus - Animal Models Disclosure: Nothing to Disclose Cope, Andrew P Rheumatoid Arthritis - Human Etiology and Pathogenesis: Anti-CCP in RA Etiology and Pathogenesis II Disclosure: Nothing to Disclose Cornell, Patricia J, BSc Issues in Lupus Disclosure:Nothing to Disclose Criswell, Lindsey A Genetics, Genomics and Proteomics: RA and Other Rheumatic Diseases Disclosure: Nothing to Disclose Cronstein, Bruce N Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Disclosure: Can-Fite Biopharmaceuticals, 1; Endocyte, 5; King Pharmaceuticals, 7; NIH, 2; NYU SoM, 9; OSI Pharmaceuticals, 2; Regeneron, 5 URL, 5 Curtis, Jeffrey R, MD, MPH Epidemiology and Health Services Research: Gout Disclosure:Nothing to Disclose D DallEra, Maria Systemic Lupus Erythematosus - Clinical Aspects and Treatment: New Therapies Disclosure: Nothing to Disclose De Pablo, Paola, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: SLE and Cardiovascular Disease Disclosure: Nothing to Disclose Dellaripa, Paul F, MD Rheumatoid Arthritis - Clinical Aspects: RA and Cardiovascular Disease III Disclosure:Nothing to Disclose Distler, Oliver Cytokines, Mediators, Gene Regulation I Disclosure: Actelion, Pfizer, Encysive and ERgonex, 9; Actelion, Pfizer, Encysive, FibroGen, Ergonex, NicOx, BMS, Biovitrium, 2; Biovitrium, 5 Dougados, Maxime, MD Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Therapy III Disclosure: Abbott, 2, 5; Pfizer, 2, 5; Roche, 2, 5; Sanofi, 2, 5 Espinoza, Luis R, MD Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Therapy III Disclosure:Nothing to Disclose Finnegan, Alison, PhD Cytokines, Mediators, Gene Regulation I Disclosure:Nothing to Disclose F ABSTRACT MODERATOR DISCLOSURE 2010 Program Book 375
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
Page 11 and 12:
the written consent of the ACR is p
Page 13 and 14:
Shuttle Bus Service See shuttle sig
Page 15 and 16:
ACR Resource Center Hours: Sunday,
Page 17 and 18:
ACR Hotels + Map Complimentary shut
Page 19 and 20:
to the premier meeting in rheumatol
Page 21 and 22:
ACR Clinical Research Conference c/
Page 23 and 24:
4:20 PM Germinal Center Reactions A
Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
Page 27 and 28:
Upon completion of this session, pa
Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
Page 31 and 32:
B301 Dermatological Manifestations
Page 33 and 34:
Session Overview: The innate immune
Page 35 and 36:
Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
Page 39 and 40:
and insufficiency • recall source
Page 41 and 42:
Session Overview: The advent of bio
Page 43 and 44:
2:45 pm 641. Major Improvements in
Page 45 and 46:
5 University of Twente and Medisch
Page 47 and 48:
ACR/ARHP Combined Abstract Session
Page 49 and 50:
REF 25th Anniversary Celebration 2:
Page 51 and 52:
5:45 PM 699. Defining Latent and/or
Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
Page 59 and 60:
• discuss the principles of early
Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
Page 65 and 66:
ACR Plenary Session II: Discovery 2
Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
Page 69 and 70:
Session Overview: As a clinical edu
Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
Page 77 and 78:
2:45 PM 1405. Development of a Visi
Page 79 and 80:
4:30 PM Anti-citrullinated Protein
Page 81 and 82:
of Experimental Orthopedics, Univer
Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
Page 91 and 92:
• compare the prevalence and epid
Page 93 and 94:
6:45 PM Macrophage Activation Syndr
Page 95 and 96:
Page 97 and 98:
Session Overview: This roundtable d
Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
Page 103 and 104:
• describe the role of IL-1 and I
Page 105 and 106:
Session Overview: For the clinician
Page 107 and 108:
• identify the aspects for day-to
Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
Page 111 and 112:
Session Overview: Ultrasound and ma
Page 113 and 114:
Session Overview: Fifty percent of
Page 115 and 116:
1:20 PM Academic Rheumatology Seth
Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
Page 123 and 124:
Session Overview: We are witnessing
Page 125 and 126:
Session Overview: Systemic sclerosi
Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
Page 131 and 132:
4:30 PM 2198. Association between V
Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
Page 137 and 138:
• apply these basic statistics to
Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
Page 141 and 142:
Immunology, Oslo University Hospita
Page 143 and 144:
9:15 AM 2239. Factors Associated wi
Page 145 and 146:
Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
Page 151 and 152:
ACR Poster Session A Cytokines, Med
Page 153 and 154:
ACR Poster Session A 51. Associatio
Page 155 and 156:
ACR Poster Session A 83. Respirator
Page 157 and 158:
ACR Poster Session A 121. Bone Dens
Page 159 and 160:
ACR Poster Session A 142. The Intra
Page 161 and 162:
ACR Poster Session A 171. Early Pro
Page 163 and 164:
ACR Poster Session A Pediatric Rheu
Page 165 and 166:
ACR Poster Session A 233. Prevalenc
Page 167 and 168:
ACR Poster Session A 266. Subtype S
Page 169 and 170:
ACR Poster Session A 297. Body Weig
Page 171 and 172:
ACR Poster Session A 325. Patient R
Page 173 and 174:
ACR Poster Session A 356. Influence
Page 175 and 176:
ACR Poster Session A 383. Efficacy
Page 177 and 178:
ACR Poster Session A 409. Rituximab
Page 179 and 180:
ACR Poster Session A 441. Recombina
Page 181 and 182:
ACR Poster Session A 465. Immunoglo
Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
Page 187 and 188:
ACR Poster Session A 546. Prevalenc
Page 189 and 190:
ACR Poster Session A 571. Epidemiol
Page 191 and 192:
ACR Poster Session A 599. Validatio
Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
Page 195 and 196:
ACR Poster Session B 767. Economic
Page 197 and 198:
ACR/ARHP Poster Session B 792. The
Page 199 and 200:
ACR/ARHP Poster Session B Universit
Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
Page 207 and 208:
ACR/ARHP Poster Session B 935. The
Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
Page 211 and 212:
ACR Poster Session B 993. Early Exp
Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
Page 221 and 222:
ACR Poster Session B hiroshima Memo
Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
Page 283 and 284:
REF Industry Roundtable-supported S
Page 285 and 286:
REF Industry Roundtable-supported S
Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
Page 305 and 306:
Cooper, Max D, MD Introduction . .
Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
Page 309 and 310:
Physical Examination Skills for Imp
Page 311 and 312:
Meroni, Pierluigi, MD Autoantibodie
Page 313 and 314:
Rogers, Joan C, PhD, OTR/ L Underst
Page 315 and 316:
Terkeltaub, Robert, MD Crystallizin
Page 317 and 318:
A Aarden, L 1825 Aarrass, S 1519, 1
Page 319 and 320:
Bakker, AAB 1095 Barendregt, B 753
Page 321 and 322:
Boutin-Le Thi Huong, D 478 Bout-Tab
Page 323 and 324:
Chatham, WW 457, 1146, 1454, 1457,
Page 325 and 326: Daudon, M 875 Daugas, E 2009 Davatc
Page 327 and 328: Ehst, B 758 Eicher, JL 688 Eisen, S
Page 329 and 330: Gabay, OH 1484 Gaber, T 630, 1418 G
Page 331 and 332: Guan, M 965 Guañabens, N 975 Gudbj
Page 333 and 334: Homme, CL 730 Honda, E 434 Hong, JY
Page 335 and 336: Kambayashi, T 1354 Kamdar, AA 1160
Page 337 and 338: Kuller, LH 71 Kumabe, M 1164 Kumaga
Page 339 and 340: Looney, C 941 Looney, MR 609 Looney
Page 341 and 342: McCarthy, GM 1109, 1306, 1426 McCau
Page 343 and 344: Myouzen, K 1577 Mysiw, WJ 2096 Mysl
Page 345 and 346: Pans, M 1834 Parra, ER 605, 887 Ped
Page 347 and 348: Radka, S 1174 Radner, H 296, 1745 R
Page 349 and 350: Sack, KE 1898 Sacli, SF 1312 Saddic
Page 351 and 352: 1463, 2071, 2140, 2141 Singh, K 212
Page 353 and 354: Takahata, M 1492 Takasaki, Y 1731 T
Page 355 and 356: 636 van Dongen, CJJ 90 Van Doornum,
Page 357 and 358: Witte, T 824, 1578, 1579, 2214 Witt
Page 359 and 360: A α-galactosylceramide 505 A2A kno
Page 361 and 362: Behcet’s syndrome 1284, 1288, 129
Page 363 and 364: cost-utility 759, 1539 couples 1324
Page 365 and 366: fibroblast like synoviocyte 27 fibr
Page 367 and 368: impact 1063, 1325 inactive disease
Page 369 and 370: methylation 826, 1253, 1489 methylt
Page 371 and 372: 233, 234, 240, 243, 252, 262, 268,
Page 373 and 374: 1599, 1600, 1603, 1605, 1606, 1609,
Page 375: 1226, 1227, 1229, 1230, 1231, 1233,
Page 379 and 380: Massarotti, Elena M, MD Systemic Lu
Page 381 and 382: ACR Annual Meeting fellowS-in-train
Page 383 and 384: NOTES 2010 Program Book 381
Page 385 and 386: Enbrel ® (etanercept) Brief Summar
Page 387 and 388: Prescription Enbrel ® (etanercept)
show all

B O O K - American College of Rheumatology

Create successful ePaper yourself

Delete template?

Save as template?